Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis.

Background: Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantly increases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial in these patients, but it may be underestimated using the current criteria, as they do not include nontraditional CVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarker for cardiovascular and rheumatic diseases.

Metabolomics in spondylarthritis.

Background And Aim: Spondyloarthritides (SpA) are common entities of the inflammatory rheumatic type. There are still 3 relevant problems in everyday clinical practice: early disease detection, cardiovascular risk assessment, and less so, disease activity measurement. Metabolomics allows the quantification of a large number of small-molecule substances from biological samples.

Metabolomics for Distinguishing Cardiovascular Risk in Rheumatoid Arthritis Across Different Disease-Modifying Antirheumatic Drug Therapies.

Background: Rheumatoid arthritis (RA) significantly increases the overall risk of cardiovascular disease (CVD). In addition to conventional risk factors, the inflammatory activity of the disease itself and medications that promote atherosclerosis contribute to an even greater risk. In this study, we performed metabolomic analysis in RA patients, both on and off disease-modifying anti-rheumatic drug (DMARD) therapy, with the aim of identifying new candidates for more sophisticated cardiovascular risk (CVR) assessment.

Dysregulation of amino acid and lipid metabolism in patients with spondyloarthritis.

Objective: To conduct a metabolomics analysis in patients with spondyloarthritis (SpA) and compare results with those from healthy controls. The overall goal was to identify small-molecule substances that may have potential pathogenic and diagnostic significance in SpA.

Methods: This was an observational, cross-sectional, single-centre study that included patients with axial (ankylosing spondylitis [AS]), peripheral (psoriatic arthritis [PsA]) and healthy controls.